Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MS-275 dosing schedules in metastatic melanoma
2004-002395-41Phase 2Completed
- Sponsor
- Schering AG
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of entinostat in melanoma (2 arms), sponsored by Schering AG. Primary endpoint: Overall tumor response rate within first 6 cycles. Started Oct 2004; status: completed.
02
Drugs
entinostat
03
Conditions
melanoma
Beyond the preview
Go deeper on 2004-002395-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002395-41.